Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) will work with Curia to develop the final formulation of its investigational breast cancer vaccine for a Phase 2 trial. Curia will help develop a formulation designed to improve stability and consistency and be suitable for clinical manufacturing. Anixa is developing the vaccine with Cleveland Clinic and intends the formulation work to support future studies and potential commercial production.
The Phase 1 trial met its primary endpoints in a study involving 35 women and showed a favorable safety and tolerability profile. 74% of participants showed immune responses as defined by the trial protocol. The vaccine is designed to help the immune system recognize alpha-lactalbumin, a protein expressed in many breast cancers. Anixa is preparing for Phase 2 to further evaluate potential clinical benefits.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointPhase 1 trial met its primary endpoints in a study involving 35 women
- Moderate point. Forward-looking: it has not happened yet and may not happen.Curia collaboration will support final formulation development for Phase 2 and potential commercial production
- Minor pointProtocol-defined immune responses occurred in 74% of Phase 1 participants
- Minor pointPhase 1 safety and tolerability showed a favorable profile
Negative
- None.
Key Figures
- Phase 1 participants
- 35 women
- Breast cancer vaccine trial
- Protocol-defined immune responses
- 74%
- Phase 1 breast cancer vaccine trial participants
Key Terms
cdmo technical
primary endpoints medical
alpha-lactalbumin medical
aseptic manufacturing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Collaboration to support development of a stable, scalable formulation for clinical development and potential commercialization
Under the collaboration, Curia will support the development of a formulation designed to optimize the vaccine's stability, consistency, and suitability for clinical manufacturing. This work represents an important step in Anixa's preparations for Phase 2 and is intended to establish a formulation and development process capable of supporting future clinical studies and potential commercial production.
"Selection of Curia is another important milestone as we prepare to advance our breast cancer vaccine into Phase 2 clinical development," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Our Phase 1 trial demonstrated encouraging safety and immune-response results, and we are now focused on the activities necessary to support the next stage of clinical testing. Curia brings extensive expertise in pharmaceutical formulation and manufacturing processes, and we believe their capabilities will be valuable as we work toward developing a vaccine that could ultimately help prevent breast cancer."
"Curia looks forward to providing formulation development support for Anixa's peptide cancer vaccine," said Ranald Baillie, VP, Drug Product Development and General Manager at Curia Glasgow. "Successful formulation and product development requires looking beyond the formulation itself to understand stability, analytical performance, scalability and the requirements of aseptic manufacturing. Curia's integrated expertise allows us to address those considerations early and develop robust processes designed to support Anixa as it advances this vaccine towards commercialization."
Anixa's investigational breast cancer vaccine is designed to stimulate the immune system to recognize alpha-lactalbumin, a protein expressed in many breast cancers. The vaccine recently completed a Phase 1 clinical trial involving 35 women, meeting its primary endpoints and demonstrating a favorable safety and tolerability profile, with
About Curia
Curia is a global contract development and manufacturing organization with more than 30 years of experience supporting pharmaceutical and biotechnology companies through drug discovery, development, and manufacturing. With an extensive global network of facilities, Curia provides integrated services spanning formulation development, analytical testing, process development, clinical manufacturing, and commercial production. Its
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-and-curia-will-develop-final-formulation-for-breast-cancer-vaccine-in-preparation-for-phase-2-clinical-trial-302943033.html
SOURCE Anixa Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.